Unlimited Quote Collections
Organize your favorite quotes without limits. Create themed collections for every occasion with Premium.
One reason... to move our scientists to Houston was to take advantage of being located within the [TMC]... comprising more than 50 biomedical institu… - Peter J. Hotez
" "One reason... to move our scientists to Houston was to take advantage of being located within the [TMC]... comprising more than 50 biomedical institutions and 100,000 employees, occupying a building space that exceeds that of downtown Los Angeles. A second reason... generous support from Texas Children's Hospital (the world's largest...) which also housed the Sabin Vaccine Institute PDP... Our goal for moving and becoming linked to the TMC was to increase the number of new vaccines we are creating for the poorest people in less developed countries, [and] to accelerate the pace at which they are produced. ...[T]oday we have two vaccines in clinical trials—with others in various stages of development.
English
Collect this quote
About Peter J. Hotez
(born 5 May 1958) is an American scientist, pediatrician, and advocate in the fields of , vaccinology, and neglected tropical disease control. He serves as founding dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at , where he is also Director of the Center for Vaccine Development and Texas Children’s Hospital Endowed Chair in Tropical Pediatrics. Hotez served previously as President of the and is a founding Editor-in-Chief of . He is also the co-director of Parasites Without Borders, a global nonprofit organization with a focus on those suffering from parasitic diseases in subtropical environments.
Also Known As
Alternative Names:
Peter J Hotez
•
Peter Hotez
•
P. J. Hotez
•
P J Hotez
•
P. Hotez
•
P Hotez
•
Hotez P
•
Hotez P.
•
Hotez P. J.
•
Hotez PJ
•
Peter Jay Hotez
Related quotes. More quotes will automatically load as you scroll down, or you can use the load more buttons.
Additional quotes by Peter J. Hotez
So we have a vaccine now in clinical trials, a vaccine that we hope will advance to the clinic soon, a Hookworm vaccine in clinical trials, a new vaccine that's moving into the clinic. I like to say that these are the most important diseases that you've never heard of. These are some of the most common afflictions of the world's population, but they mostly occur among people who live in extreme poverty... [S]o there is no model to figure out who's going to pay for them. So as a consequence, neither the biotechs nor the big pharmaceutical companies make those vaccines.
PREMIUM FEATURE
Advanced Search Filters
Filter search results by source, date, and more with our premium search tools.
[O]ne of the things that we're not hearing a lot about is the unique potential safety problem of Coronavirus vaccines. ...This was first found in the early 1960s with the respiratory syncytial virus [RSV] vaccines, and it was done here in Washington with the NIH and Children's National Medical Center... [S]ome of those kids that got the vaccine actually did worse, and I believe that there were two deaths in the consequence of that study. ...[W]hat happens with certain types of respiratory virus vaccines, you get immunized, and then when you get actually exposed to the virus you get this kind of paradoxical immune enhancement phenomenon. ...[I]t's a real problem for certain respiratory virus vaccines. That killed the RSV program for decades. Now the Gates Foundation is taking it up again, but when we started developing Coronavirus vaccines (and our colleagues) we noticed in laboratory animals, that they started to show some of the same immune pathology that resembled what had happened 50 years earlier.
Loading...